Nov. 14, 2022 – The public health landscape has changed dramatically since the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (Pasteur Act) – a bill that would address the significant and growing problem of antibiotic, antifungal and antiviral resistance – was introduced three years ago and every year since, but despite the ongoing need […]
Read more
Aug. 30, 2022 – When members of the House and Senate return to Washington Sept. 6 following the Labor Day holiday, they face competing priorities and tight timeframes to take action on the federal budget and user fees, which expire on Sept. 30. Failure to pass the fiscal year 2023 (FY 2023) budget and reauthorize […]
Read more
Aug. 22, 2022 – For years, the issue of regulating data privacy has been addressed largely by individual states, with little comprehensive action on the federal level. But that may be about to change in light of a more aggressive Federal Trade Commission (FTC), a new bipartisan proposal in Congress, and the U.S. Supreme Court’s […]
Read more
March 24, 2022 – By Jay Carter, EVP/Director of Business Development, AbelsonTaylor In remarks I made recently at the 2022 Medical Advertising Hall of Fame gala, I asked the following questions, which I think are especially applicable here: Do you work on communications to consumers or patients regularly? Do you work on digital initiatives as […]
Read more Feb. 14, 2022 – Negotiations for prescription drug and medical device user fee legislation are running behind schedule and legislators are concerned about the timeline for the Prescription Drug User Fee Amendments VII (PDUFA VII), the Medical Device User Fee Amendments (MDUFA) and other user fee bills. Because the Food and Drug Administration (FDA) receives […]
Read more
Jan. 24, 2022 – With the COVID-19 pandemic heading into year three, the Food and Drug Administration (FDA) faces ongoing challenges but continues to work on four primary agency priorities, according to Nancy Bradish Myers, president of Catalyst Healthcare Consulting, who spoke at a Jan. 21 Coalition for Healthcare Communication webinar, “A New Start for […]
Read more June 29, 2021 – In the wake of the FDA granting a controversial accelerated approval for Biogen’s aducanumab (Aduhelm) – and Biogen’s decision to set the list price for the drug for Alzheimer’s disease at $56,000 per year despite equivocal evidence of efficacy – members of Congress are introducing drug pricing legislation, calling for hearings, […]
Read more Jan. 5, 2021 – The just-enacted COVID-19 relief bill may be a harbinger of what is to come in 2021 for drug pricing and marketing tax proposals, according to Coalition for Healthcare Communication Executive Director Jon Bigelow. In a memo to Coalition members and industry leaders, Bigelow noted that it had been fairly clear weeks […]
Read more March 30, 2020 – In addition to providing millions of Americans and many industries with financial support during the coronavirus outbreak, the emergency relief bill passed by Congress and signed into law by President Donald Trump on Friday accrues additional funding for the Food and Drug Administration’s coronavirus efforts and makes important changes to how […]
Read more
Aug. 19, 2019 – As presidential hopefuls discuss the possible merits of “Medicare for All” and other healthcare reforms, discourse in the nation’s capital has deteriorated to the point where “no one talks to each other,” according to Kay Holcombe, who recently retired as senior vice president for science policy at the Biotechnology Innovation Organization. […]
Read more